The COVID‑19 pandemic showed that mRNA vaccines can protect people quickly. Scientists are now using the same technology to make vaccines that target cancer. Early tests are already happening for melanoma, small‑cell lung cancer, bladder cancer, and more.
What the New Study Found
Researchers at Washington University in St. Louis studied mice that received an mRNA cancer vaccine. They expected a special immune cell called cDC1 to be essential for the vaccine to work. Surprisingly, the mice still fought the tumors even when they lacked cDC1 cells.
Instead, another cell type called cDC2 stepped in and helped the immune system attack the cancer. This shows that both cDC1 and cDC2 can drive the vaccine’s protection.
How mRNA Cancer Vaccines Work
An mRNA vaccine carries a tiny piece of genetic code. When the code enters a cell, the cell makes a short protein that is unique to the tumor. The immune system learns to recognize this protein and then hunts down any cell that shows it.
Dendritic cells are the “teachers” of the immune system. They pick up the tumor protein, break it into smaller pieces, and show those pieces to T cells. The T cells then become soldiers that seek and destroy cancer cells.
The Unexpected Helper: cDC2 Cells
When cDC1 cells were missing, cDC2 cells still managed to activate T cells. The T cells they trained looked slightly different from those taught by cDC1, suggesting the two dendritic cells may work together for a stronger response.
Further tests showed that cDC2 cells do not make the vaccine protein themselves. Instead, they receive the protein fragments from other cells through a process known as “cross‑dressing.” This lets cDC2 present the tumor pieces to T cells and start the attack.
Why This Matters
Understanding that both cDC1 and cDC2 are important gives scientists new targets for improving mRNA cancer vaccines. It could help them design better doses, choose the right patients, and create stronger, safer cancer treatments.